ArticleObstetrics & gynecology science2025
Validation of adopting vaginal natural orifice transluminal endoscopic surgery for risk-reducing salpingo-oophorectomy for women with germline BRCA1/2 pathogenic variants analysis from conventional procedure.
Article in Obstetrics & gynecology science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveVaginal natural orifice transluminal endoscopic surgery (vNOTES) is less invasive than conventional transabdominal laparoscopic surgery for benign gynecological indications. When adopting this procedure for risk-reducing salpingo-oophorectomy (RRSO) in women with hereditary breast and ovarian cancer (HBOC), the ventral side of the uterus becomes a blind area, which is a challenge. To clarify the effects of this blind area on the treatment outcome of HBOC, we examined the clinical data of RRSO using conventional procedures for women with germline BRCA1/2 pathogenic variants who were treated at our institution.
methodsA retrospective chart review was performed. The clinical data of patients who underwent RRSO using the conventional procedure between September 2011 and July 2024 were extracted. All included patients were preoperatively examined using vaginal ultrasonography, contrast-enhanced pelvic magnetic resonance imaging, and carcinoma antigen-125 level measurements to exclude ovarian cancer development.
resultsA total of 267 patients underwent RRSO at our institution. The mean age at RRSO was 50.1 years. Five cases of occult invasive cancer (1.9%) and 10 cases of serous tubal intraepithelial carcinoma (3.7%) were identified postoperatively. One patient (0.37%) showed macroscopic peritoneal dissemination in the omentum. None of the 252 patients without occult cancer developed peritoneal cancer during the mean observational time of 62.4 months. No patient presented with peritoneal lesions ventral to the uterus.
conclusionMacroscopic tumors on the peritoneum ventral to the uterus were rare when strict preoperative screening for ovarian cancer was performed. vNOTES can be safely adopted for RRSO in patients with HBOC, without evident disadvantages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.